BESREMi FDA Approval: First New ET Drug in Three Decades

The FDA approved PharmaEssentia’s BESREMi (ropeginterferon alfa-2b-njft) for adults with essential thrombocythemia (ET) on August 31, handing the rare blood cancer its first new treatment in nearly three decades. The approval widens BESREMi’s label beyond polycythemia vera (PV), the related myeloproliferative neoplasm (MPN) the drug has treated since its 2021 US approval.

ET makes the bone marrow overproduce platelets, which raises the risk of blood clots, stroke, and heart attack, and patients often need years of ongoing management. BESREMi uses monopegylation to stretch its half-life, so the long-acting interferon can target disease-driving cells in the bone marrow over months rather than the short window of standard interferon.

In the Phase 3 SURPASS-ET trial of 174 patients resistant or intolerant to hydroxyurea, BESREMi produced a durable modified ELN response in 42.9% of patients at months 9 and 12, versus 6.0% for anagrelide (p=.0001), a sevenfold advantage. The interferon also cut thromboembolic and cardiovascular events to 1.1%, against 10% for anagrelide, and shrank the JAK2 V617F allele burden, evidence that it works at the source of the disease instead of just lowering platelet counts. On safety, the tradeoff is interferon’s known flu-like symptoms and fatigue, but tolerability still favored BESREMi: 5.5% of patients discontinued for adverse events versus 18.8% on anagrelide, and treatment-related serious adverse events ran 2.2% versus 10.0%.

The label covers adults regardless of genotype or disease status, including newly diagnosed patients not yet on cytoreductive therapy. A companion single-arm North American study, EXCEED-ET, showed responses across the JAK2, CALR, and MPL driver mutations, supporting the broad label, and BESREMi holds orphan drug designation for both PV and ET. The incumbent anagrelide dates to 1997, and hydroxyurea, the other mainstay, is even older, which is why the first-new-drug-in-decades framing matters. PharmaEssentia is based in Taipei and trades only on the Taiwan exchange (TWSE: 6446), so there is no US ticker to follow; US sales run through its Burlington, Massachusetts subsidiary. Taiwan and Japan cleared BESREMi for ET earlier this year, making the United States the newest major market in the company’s MPN franchise, and PharmaEssentia retains global rights to BESREMi across all indications.

BESREMi’s PV business also got a new competitor this week, when the FDA approved Protagonist’s rusfertide for the sister indication polycythemia vera; in ET, by contrast, BESREMi faces essentially no direct competition. PharmaEssentia announced the approval on August 31, and the drug is expected to be available in the US immediately.

What to watch next: launch execution and whether BESREMi can convert its head-to-head win over anagrelide into real ET market share now that the label is broad enough to cover newly diagnosed patients.

What It Means for the Trade

With no U.S. ticker, the tradeable content is the competitive read-through, and there are two. The direct one: PharmaEssentia’s ET label reshapes the addressable market for anyone with MPN assets — most immediately, it puts a disease-modifying interferon into an indication where the standard of care (hydroxyurea, anagrelide) is purely cytoreductive platelet-count management. The second read is the contrast with the PV franchise news the same week: rusfertide’s approval gives polycythemia vera a new mechanism, but in ET, PharmaEssentia faces essentially no direct competition — the first-new-drug-in-three-decades headline is literally accurate, and the incumbents being a 1997 drug and generic hydroxyurea means the reimbursement bar is low while the differentiation is high.

The head-to-head structure of SURPASS-ET is what makes the label commercially potent. A 42.9% versus 6.0% durable response against anagrelide (p=0.0001) is not a marginal win; it is a sevenfold advantage with a thromboembolic event rate of 1.1% versus 10% and better discontinuation and serious-event numbers. Oncologists in MPN do not see that kind of comparative data often — most approvals in this space rest on single-arm or non-inferiority designs. The allele-burden data (JAK2 V617F reduction) adds the disease-modification claim that lets PharmaEssentia position BESREMi as the only ET therapy that changes the disease’s biology rather than its blood counts, and EXCEED-ET’s responses across JAK2, CALR, and MPL mutations support the genotype-agnostic label.

Mechanism and Market Context

The mechanism argument is the oldest one in hematology wearing new pharmacology. Interferon has been understood to suppress malignant hematopoietic clones in MPNs since the pre-JAK-inhibitor era — the problem was always tolerability and dosing burden with short-acting formulations. Ropeginterferon’s monopegylation extends the half-life enough for once-every-two-weeks-then-monthly dosing, which converts a drug class patients quit into one they stay on: the 5.5% discontinuation rate versus anagrelide’s 18.8% is the tolerability story in one line. For ET specifically, the clinical goal is dual — pull platelets down to cut clot risk, and ideally reduce the clone driving the overproduction. Anagrelide and hydroxyurea do the first and not the second, and hydroxyurea carries its own long-term leukemogenesis questions that MPN specialists weigh.

The market shape matters for underwriting: ET is the most common MPN, diagnosed across adult ages, and managed for decades — a chronic-disease revenue profile, not a one-course orphan drug. Interferon’s known flu-like onset period is the adoption friction that a specialty sales force can manage with dose-titration education; the label covering newly diagnosed patients means the launch competes at the first treatment decision, not just in the hydroxyurea-failure salvage pool.

Risks and What Could Go Wrong

1. Interferon psychology: a generation of hematologists trained to avoid interferon’s side-effect reputation may default to the familiar cheap generics, and a Taiwan-listed company’s U.S. subsidiary may lack the sales force weight to shift that instinct.
2. Anagrelide and hydroxyurea are generic-priced — payer coverage for a premium biologic in a cancer managed largely in community clinics will require the thrombosis data to win prior-auth battles.
3. Rusfertide’s PV success emboldens mechanism-first competitors to chase ET next; the no-competition window is real but finite.
4. The long-term interferon risk profile in a decades-long indication — fatigue, mood effects, cytopenias — is exactly what the sevenfold response advantage has to keep outweighing at year five.

Position read: no direct equity exposure for U.S. traders short of TWSE access, but the read-through is clean — this approval raises the bar for every ET-directed program in development and gives the MPN franchise landscape its first real disease-modifying entrant. If a partner or U.S. listing ever materializes, the head-to-head dataset is the asset.